Amarin's (NAS: AMRN) share price took a hit this month after the Food and Drug Administration announced that it has still not decided whether the company's flagship drug, Vascepa, qualifies for New Chemical Entity, or NCE, status. Shares of Amarin are up today, however, on news that two new patents have been approved for Vascepa.
Although patents are an essential long-term shield against generic competition, will this really move the needle for Amarin's stock in the short term? Is NCE status still the biggest catalyst that investors need to watch?
In the following video, health care analysts Max Macaluso and Brenton Flynn discuss these issues.
The biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future. The company has huge potential and a number of risks -- so don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.
The article Will These Patents Help Amarin Shareholders? originally appeared on Fool.com.
Max Macaluso, Ph.D. and Brenton Flynn hold no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Abbott Laboratories. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.